What Edwards Lifesciences Corporation's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 9 | 54 |
| Total trades | 17 | 157 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 33,657 | 589,373 |
| Disposed | 39,805 | 470,314 |
| Net activity | −6,148 | +119,058 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lippis Daniel J. | CVP, TAVR | Oct 08 | Disclosed 10b5-1 sale · S | −619 | $85.65 | −$53K | 40,034 |
| Lippis Daniel J. | CVP, TAVR | Oct 08 | Exercise / conversion · M | +619 | $72.68 | +$45K | 40,653 |
| Markowitz Wayne | CVP, JAPAC | Sep 14 | Withheld — tax / exercise cost · F | −568 | $84.37 | −$47.9K | 19,371 |
| Dahl Andrew M. | SVP, Corporate Controller | Sep 13 | Withheld — tax / exercise cost · F | −253 | $84.37 | −$21.3K | 14,615 |
| Markowitz Wayne | CVP, JAPAC | Sep 11 | Withheld — tax / exercise cost · F | −355 | $86.77 | −$30.8K | 19,939 |
| Lippis Daniel J. | CVP, TAVR | Sep 11 | Disclosed 10b5-1 sale · S | −619 | $87.51 | −$54.2K | 40,034 |
| Lippis Daniel J. | CVP, TAVR | Sep 11 | Exercise / conversion · M | +619 | $72.68 | +$45K | 40,653 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Sep 11 | Withheld — tax / exercise cost · F | −398 | $86.77 | −$34.5K | 43,926 |
| Dahl Andrew M. | SVP, Corporate Controller | Aug 31 | Open-market sale · S | −544 | $91.06 | −$49.5K | 14,868 |
| Bruls Annette | CVP, EMEACLA | Aug 28 | Open-market sale · S | −2,644 | $89.98 | −$238K | 17,984 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Aug 26 | Open-market sale · S | −30,646 | $90.99 | −$2.79M | 44,324 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Aug 26 | Open-market sale · S | −1,154 | $91.76 | −$106K | 74,970 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Aug 26 | Exercise / conversion · M | +31,800 | $72.68 | +$2.31M | 76,124 |
| Markowitz Wayne | CVP, JAPAC | Aug 26 | Open-market sale · S | −1,240 | $91.47 | −$113K | 20,294 |
| Lippis Daniel J. | CVP, TAVR | Aug 11 | Disclosed 10b5-1 sale · S | −619 | $92.03 | −$57K | 40,034 |
| Lippis Daniel J. | CVP, TAVR | Aug 11 | Exercise / conversion · M | +619 | $72.68 | +$45K | 40,653 |
| Markowitz Wayne | CVP, JAPAC | Jul 30 | Open-market sale · S | −146 | $86.03 | −$12.6K | 21,534 |
| Markowitz Wayne | CVP, JAPAC | Jul 28 | Open-market sale · S | −9,628 | $85.06 | −$819K | 21,680 |
| Markowitz Wayne | CVP, JAPAC | Jul 28 | Exercise / conversion · M | +9,628 | $74.02 | +$713K | 31,308 |
| Zovighian Bernard J | CEO | Jul 27 | Open-market sale · S | −2,921 | $83.93 | −$245K | 8,916 |
Loading...